Clinical Trial

aDAPt-ANOCA: Dapagliflozin for the Treatment of Angina With Non-Obstructive Coronary Artery Disease (ANOCA)

Name: aDAPt-ANOCA: Dapagliflozin for the Treatment of Angina With Non-Obstructive Coronary Artery Disease (ANOCA) — clinical trial record (NCT07741890)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: aDAPt-ANOCA

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The primary purpose of this study is to evaluate the efficacy of DAPA for the treatment of coronary microvascular dysfunction (CMD) among patients with angina and no obstructive coronary artery disease (ANOCA) and established CMD as compared to placebo.

Trial Details

NCT Number	NCT07741890
Lead Sponsor	The Christ Hospital
Conditions	Angina With Non-Obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction (CMD)
Enrollment	120 participants
Start Date	2026-09-01
Primary Completion	2028-12-01 (estimated)
Study Completion	2029-03-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-03